Search

everythinglearnresearchcommunity

for

Search:↓

The conclusion of this conversation about hair loss is that genetics play a significant role in determining hair loss, and specific treatments like finasteride may not be effective against certain compounds like masteron and trenbolone.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

The conversation is about starting finasteride for hair loss, with concerns about high free testosterone and potential side effects like gynecomastia. The user plans to address vitamin deficiencies before beginning the treatment.

A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

Switching from finasteride to dutasteride and back to finasteride led to gynecomastia and fatigue, likely due to hormonal imbalances. Suggested treatments include Tamoxifen, Raloxifene, or low-dose Anastrozole, with a recommendation to test testosterone and estradiol levels.

The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.

A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.

A vegetarian with IBS is considering reintroducing fish to improve gut and hair health due to protein concerns. Suggestions include adding tofu, avoiding vegan protein shakes, and considering a more carb/fat dominant diet.

Discouragement regarding Pyrilutamide, a drug in development for hair loss, and the potential side effects of Finasteride. People discussed anecdotal experiences with Pyrilutamide as well as suggestions to wait out Phase 3 trials before making any conclusions.

Nearly 40% of adults with alopecia areata achieved at least 80% scalp hair coverage after 52 weeks of taking OLUMIANT® 4-mg. The conversation distinguishes this success from androgenetic alopecia, which is a different type of hair loss.

The conversation discusses using scalp antiandrogens like RU58841, pyrilutamide, or fluridil on the face to reduce sebum production, noting that clascoterone (winlevi) is an approved facial antiandrogen with underwhelming reviews.

Creatine may increase DHT levels, potentially causing symptoms like acne, oily hair, and hair shedding. Users report mixed experiences, with some avoiding creatine due to hair loss concerns and others seeing no impact.

Tretinoin combined with minoxidil may improve hair regrowth, especially in difficult areas like temples, but requires diligent scalp cleaning. Some users suggest oral minoxidil as a more potent and less irritating alternative.

A satirical post where someone claims to have developed a radioactive isotope scalp serum using Polonium-210 that outperforms Minoxidil and finasteride for hair regrowth. The serum reportedly stimulates DNA repair in hair follicles, leading to significant hair density increase, but the post is met with skepticism and concerns about safety.

A 23-year-old has been using minoxidil, finasteride, 2% ketoconazole shampoo, biotin, a multivitamin, and microneedling to address hair loss, noticing baby hairs and a fuller frontal hairline but concerns about a thin right temple. They are considering adding rosemary oil and switching to a 1.5 mm dermastamp for further improvement.

A user is using topical finasteride, keto shampoo, microneedling, and tretinoin for hair loss and is considering adding pyrilutamide. They notice some improvement at the temples and seek advice on whether to focus on cosmetic results despite daily shedding.

A 29-year-old male on 1 mg Finasteride for 3 months has experienced a significant increase in testosterone and estradiol levels, with no major side effects except slightly oilier skin and increased emotional sensitivity. The user is concerned about these hormonal changes and seeks advice, as their general practitioner is not knowledgeable about the issue.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

Topical 1% cetirizine is more effective for hair growth than 10 mg oral cetirizine. It can be ordered online from specific hair loss companies.

Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.

The conversation discusses whether individuals using hair loss treatments like Dutasteride (Dut) or Finasteride (Fin) should regularly check their hormone levels through bloodwork. Some argue it's important to monitor the effects of these medications on hormone levels, while others believe it's unnecessary if there are no side effects, citing cost and practicality concerns.

The user experienced severe scalp itching and hair loss while on dutasteride, which they linked to caffeine and masturbation. They plan to cut out both to see if their hair density improves.

Topical melatonin may help reduce hair loss and increase hair thickness in people with androgenetic alopecia (AGA), with some studies showing positive results. It can be mixed with minoxidil for application, and its effectiveness might be enhanced when used with micro-needling, but results may vary among individuals.

The conversation discusses switching from RU58841 to pyrilutamide for hair loss treatment, with users generally recommending staying on RU58841 if it is effective. RU58841 is sourced from GeneTherica, which ships worldwide.

The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.

The user experienced severe hair shedding despite using oral finasteride, minoxidil, dutasteride, and RU58841, and was diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD). They are considering switching to topical treatments due to the ineffectiveness of their current regimen.

The conversation discusses the confusion over low testosterone potentially causing hair loss, with users sharing personal experiences and knowledge about hair loss treatments like Finasteride. Some users suggest that hair follicle sensitivity to DHT, not testosterone levels, is the key factor in balding, and others discuss the side effects of hair loss medications.

The conversation is about skepticism towards the hair loss treatments RU58841 and Pyrilutamide, with users discussing the lack of human testing for RU58841 and the ongoing trials for Pyrilutamide. Some users believe RU58841 has more anecdotal success, while others highlight Pyrilutamide's current research progress.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.